The role of airway secretions in COPD: Pathophysiology, epidemiology and pharmacotherapeutic options

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 2, Issue 3, 2005, Pages 341-353

  Rogers, Duncan F ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Airway inflammation; Chronic obstructive pulmonary disease; Erythromycin; Goblet cell; MUC gene; Mucin

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ACETYLCYSTEINE; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ANTISENSE OLIGONUCLEOTIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BEZAFIBRATE; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLARITHROMYCIN; CORTICOSTEROID; DIQUAFOSOL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERDOSTEINE; ERYTHROMYCIN; EXPECTORANT AGENT; FLURITHROMYCIN; GEFITINIB; GLUCOCORTICOID; GW 273629; IODINATED GLYCEROL; LAPATINIB; MACROLIDE; MARCKS PROTEIN; METHYLXANTHINE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MSI 1956; MUCOLYTIC AGENT; MUNC18 PROTEIN; PELITINIB; PROTEIN BCL 2; PROTEIN INHIBITOR; PURINERGIC RECEPTOR BLOCKING AGENT; TACHYKININ RECEPTOR ANTAGONIST; THIOL DERIVATIVE; UNINDEXED DRUG; UO 126;

APOPTOSIS; CELL HYPERPLASIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE PREDISPOSITION; DRUG THERAPY; EXOCYTOSIS; GOBLET CELL; HUMAN; MUCUS; NERVE CONDUCTION; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SECRETION; SYNTHESIS;

HUMANS; MUCUS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY MUCOSA; RESPIRATORY SYSTEM AGENTS; SPUTUM;

EID: 33645507720     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1080/15412550500218098     Document Type: Review

References (126)

1. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977; 1:1645-1648.
2. Peto R, Speizer FE, Cochrane AL, Moore F, Fletcher CM, Tinker CM, Higgins IT, Gray RG, Richards SM, Gilliland J, Norman-Smith B. The relevance in adults of air-flow obstruction, but not of mucus hypersecretion, to mortality from chronic lung disease. Results from 20 years of prospective observation. Am Rev Respir Dis 1983; 128:491-500.
3. Fletcher CM, Pride NB. Definitions of emphysema, chronic bronchitis, asthma, and airflow obstruction: 25 years on from the Ciba symposium. Thorax 1984; 39:81-85.
4. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136:225-244.
5. National Heart Lung and Blood Institute/WHO. Global Initiative for Chronic Obstructive Lung Disease. Publication No. 2701, National Institutes of Health, 2001.
6. National Institute for Clinical Excellence (NICE). Chronic obstructive pulmonary disease: national clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004; 59.
7. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004; 364:709-721.
8. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J 1995; 8:1333-1338.
9. Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 2002; 109:571-577.
10. Morgenroth K, Bolz J. Morphological features of the interaction between mucus and surfactant on the bronchial mucosa. Respiration 1985; 47:225-231.
11. Schurch S, Gehr P, Im Hof V, Geiser M, Green F. Surfactant displaces particles toward the epithelium in airways and alveoli. Respir Physiol 1990; 80:17-32.
12. Davies JR, Herrmann A, Russell W, Svitacheva N, Wickström C, Carlstedt I. Respiratory tract mucins: structure and expression patterns. In: Mucus Hypersecretion in Respiratory Disease. Chichester: John Wiley & Sons, 2002:76-93.
13. Rogers DF. The airway goblet cell. Int. J. Biochem. Cell Biol. 2003; 35:1-6.
14. Finkbeiner WE. Physiology and pathology of tracheobronchial glands. Respir Physiol 1999; 118:77-83.
15. Verdugo P. Molecular biophysics of mucin secretion. In: Takishima T, Shimura S, eds. Airway Secretion. New York: Marcel Dekker, 1994:101-121.
16. Dekker J, Rossen JW, Buller HA, Einerhand AW. The MUC family: an obituary. Trends Biochem Sci 2002; 27:126-131.
17. Gum JR Jr, Crawley SC, Hicks JW, Szymkowski DE, Kim YS. MUC17, a novel membrane-tethered mucin. Biochem Biophys Res Commun 2002; 291:466-475.
18. Moniaux N, Escande F, Porchet N, Aubert JP, Batra SK. Structural organization and classification of the human mucin genes. Front Biosci 2001; 6:D1192-D1206.
19. Wu GJ, Wu MW, Wang SW, Liu Z, Qu P, Peng Q, Yang H, Varma VA, Sun QC, Petros JA, Lim SD, Amin MB. Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression. Gene 2001; 279:17-31.
20. Chen Y, Zhao YH, Kalaslavadi TB, Hamati E, Nehrke K, Le AD, Ann DK, Wu R. Genome-wide search and identification of a novel gel-forming mucin MUC19/Muc19 in glandular tissues. Am J Respir Cell Mol Biol 2004; 30:155-165.
21. Higuchi T, Orita T, Nakanishi S, Katsuya K, Watanabe H, Yamasaki Y, Waga I, Nanayama T, Yamamoto Y, Munger W, Sun HW, Falk RJ, Jennette JC, Alcorta DA, Li H, Yamamoto T, Saito Y, Nakamura M. Molecular cloning, genomic structure, and expression analysis of MUC20, a novel mucin protein, up-regulated in injured kidney. J Biol Chem 2004; 279:1968-1979.
22. Rogers DF. Mucus pathophysiology in COPD: differences to asthma, and pharmacotherapy. Monaldi Arch Chest Dis 2000; 55:324-332.
23. Jeffery PK. Comparison of the structural and inflammatory features of COPD and asthma. Giles F. Filley Lecture. Chest 2000; 117:251S-260S.
24. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004; 56:515-548.
25. Reid L. Pathology of chronic bronchitis. Lancet 1954; i:275-278.
26. Aikawa T, Shimura S, Sasaki H, Takishima T, Yaegashi H, Takahashi T. Morphometric analysis of intraluminal mucus in airways in chronic obstructive pulmonary disease. Am Rev Respir Dis 1989; 140:477-482.
27. Steiger D, Fahy J, Boushey H, Finkbeiner WE, Basbaum C. Use of mucin antibodies and cDNA probes to quantify hypersecretion in vivo in human airways. Am J Respir Cell Mol Biol 1994; 10:538-545.
28. Mullen JB, Wright JL, Wiggs BR, Pare PD, Hogg JC. Structure of central airways in current smokers and ex-smokers with and without mucus hypersecretion: relationship to lung function. Thorax 1987; 42:843-848.
29. Reid L. Measurement of the bronchial mucous gland layer: a diagnostic yardstick in chronic bronchitis. Thorax 1960; 15:132-141.
30. Restrepo G, Heard BE. The size of the bronchial glands in chronic bronchitis. J Pathol Bacteriol 1963; 85:305-310.
31. Glynn AA, Michaels L. Bronchial biopsy in chronic bronchitis and asthma. Thorax 1960; 15:142-153.
32. Jamal K, Cooney TP, Fleetham JA, Thurlbeck WM. Chronic bronchitis. Correlation of morphologic findings to sputum production and flow rates. Am Rev Respir Dis 1984; 129:719-722.
33. Hayes JA. Distribution of bronchial gland measurement in a Jamaican population. Thorax 1960; 24:619-622.
34. Thurlbeck WM, Angus CW, Paré JAP. Mucous gland hypertrophy in chronic bronchitis, and its occurrence in smokers. Br J Dis Chest 1963; 57:73-78.
35. Thurlbeck WM, Angus GE. A distribution curve for chronic bronchitis. Thorax 1964; 19:436-442.
36. Davies JR, Hovenberg HW, Linden CJ, Howard R, Richardson PS, Sheehan JK, Carlstedt I. Mucins in airway secretions from healthy and chronic bronchitic subjects. Biochem J 1996; 313:431-439.
37. Thornton DJ, Carlstedt I, Howard M, Devine PL, Price MR, Sheehan JK. Respiratory mucins: identification of core proteins and glycoforms. Biochem J 1996; 316:967-975.
38. Hovenberg HW, Davies JR, Herrmann A, Linden CJ, Carlstedt I. MUC5AC, but not MUC2, is a prominent mucin in respiratory secretions. Glycoconj J 1996; 13:839-847.
39. Wickstrom C, Davies JR, Eriksen GV, Veerman EC, Carlstedt I. MUC5B is a major gel-forming, oligomeric mucin from human salivary gland, respiratory tract and endocervix: identification of glycoforms and C-terminal cleavage. Biochem J 1998; 334:685-693.
40. Sheehan JK, Howard M, Richardson PS, Longwill T, Thornton DJ. Physical characterization of a low-charge glycoform of the MUC5B mucin comprising the gel-phase of an asthmatic respiratory mucous plug. Biochem J 1999; 338:507-513.
41. Kirkham S, Sheehan JK, Knight D, Richardson PS, Thornton DJ. Heterogeneity of airways mucus: variations in the amounts and glycoforms of the major oligomeric mucins MUC5AC and MUC5B. Biochem J 2002; 361:537-546.
42. Basbaum CB, Jany B, Finkbeiner WE. The serous cell. Annu Rev Physiol 1990; 52:97-113.
43. Chen Y, Zhao YH, Di YP, Wu R. Characterization of human mucin 5B gene expression in airway epithelium and the genomic clone of the amino-terminal and 5′-flanking region. Am J Respir Cell Mol Biol 2001; 25:542-553.
44. Groneberg DA, Eynott PR, Lim S, Oates T, Wu R, Carlstedt I, Roberts P, McCann B, Nicholson AG, Harrison BD, Chung KF. Expression of respiratory mucins in fatal status asthmaticus and mild asthma. Histopathology 2002; 40:367-373.
45. Groneberg DA, Eynott PR, Oates T, Lim S, Wu R, Carlstedt I, Nicholson AG, Chung KF. Expression of MUC5AC and MUC5B mucins in normal and cystic fibrosis lung. Respir Med 2002; 96:81-86.
46. Davies JR, Svitacheva N, Lannefors L, Kornfalt R, Carlstedt I. Identification of MUC5B, MUC5AC and small amounts of MUC2 mucins in cystic fibrosis airway secretions. Biochem J 1999; 344(Pt 2):321-330.
47. Wanner A. Clinical aspects of mucociliary transport. Am Rev Respir Dis 1977; 116:73-125.
48. McDowell EM, Barrett LA, Harris CC, Trump BF. Abnormal cilia in human bronchial epithelium. Arch Pathol Lab Med 1976; 100:429-436.
49. Wanner A, Salathe M, O'Riordan TG. Mucociliary clearance in the airways. Am J Respir Crit Care Med 1996; 154:1868-1902.
50. Pavia D, Agnew JE, Glassman JM, Sutton PP, Lopez-Vidriero MT, Soyka JP, Clarke SW. Effects of iodopropylidene glycerol on tracheobronchial clearance in stable, chronic bronchitic patients. Eur J Respir Dis 1985; 67:177-184.
51. Moretti M, Lopez-Vidriero MT, Pavia D, Clarke SW. Relationship between bronchial reversibility and tracheobronchial clearance in patients with chronic bronchitis. Thorax 1997; 52:176-180.
52. Goodman RM, Yergin BM, Landa JF, Golivanux MH, Sackner MA. Relationship of smoking history and pulmonary function tests to tracheal mucous velocity in nonsmokers, young smokers, ex-smokers, and patients with chronic bronchitis. Am Rev Respir Dis 1978; 117:205-214.
53. Agnew JE, Little F, Pavia D, Clarke SW. Mucus clearance from the airways in chronic bronchitis - smokers and ex-smokers. Bull Eur Physiopathol Respir 1982; 18:473-484.
54. van der Schans CP, Piers DA, Beekhuis H, Koeter GH, van der Mark TW, Postma DS. Effect of forced expirations on mucus clearance in patients with chronic airflow obstruction: effect of lung recoil pressure. Thorax 1990; 45:623-627.
55. Ericsson CH, Svartengren K, Svartengren M, Mossberg B, Philipson K, Blomquist M, Camner P. Repeatability of airway deposition and tracheobronchial clearance rate over three days in chronic bronchitis. Eur Respir J 1995; 8:1886-1893.
56. Vestbo J. Epidemiological studies in mucus hypersecretion. Novartis Found Symp 2002; 248:3-12.
57. Kauffmann F, Drouet D, Lellouch J, Brille D. Twelve years spirometric changes among Paris area workers. Int J Epidemiol 1979; 8:201-212.
58. Higgins MW, Keller JB, Becker M, Howatt W, Landis JR, Rotman H, Weg JG, Higgins I. An index of risk for obstructive airways disease. Am Rev Respir Dis 1982; 125:144-151.
59. Ebi-Kryston KL. Respiratory symptoms and pulmonary function as predictors of 10-year mortality from respiratory disease, cardiovascular disease, and all causes in the Whitehall Study. J Clin Epidemiol 1988; 41:251-260.
60. Wiles FJ, Hnizdo E. Relevance of airflow obstruction and mucus hypersecretion to mortality. Respir Med 1991; 85:27-35.
61. Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med 1968; 278:1355-1360.
62. Annesi I, Kauffmann F. Is respiratory mucus hypersecretion really an innocent disorder? A 22-year mortality survey of 1,061 working men. Am Rev Respir Dis 1986; 134:688-693.
63. Vollmer WM, McCamant LE, Johnson LR, Buist AS. Respiratory symptoms, lung function, and mortality in a screening center cohort. Am J Epidemiol 1989; 129:1157-1169.
64. Speizer FE, Fay ME, Dockery DW, Ferris BG Jr. Chronic obstructive pulmonary disease mortality in six U.S. cities. Am Rev Respir Dis 1989; 140:549-555.
65. Vestbo J, Rasmussen FV. Respiratory symptoms and FEV1 as predictors of hospitalization and medication in the following 12 years due to respiratory disease. Eur Respir J 1989; 2:710-715.
66. Vestbo J, Knudsen KM, Rasmussen FV. The value of mucus hypersecretion as a predictor of mortality and hospitalization. An 11-year register based follow-up study of a random population sample of 876 men. Respir Med 1989; 83:207-211.
67. Lange P, Nyboe J, Appleyard M, Jensen G, Schnohr P. Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. Thorax 1990; 45:579-585.
68. Sherman CB, Xu X, Speizer FE, Ferris BG Jr, Weiss ST, Dockery DW. Longitudinal lung function decline in subjects with respiratory symptoms. Am Rev Respir Dis 1992; 146:855-859.
69. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153:1530-1535.
70. Miravitlles M, Guerrero T, Mayordomo C, Sanchez-Agudo L, Nicolau F, Segu JL. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration 2000; 67:495-501.
71. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med 2001; 164:358-364.
72. Rogers DF. Mucociliary dysfunction in COPD: effect of current pharmacotherapeutic options. Pulm Pharmacol Ther 2005; 18:1-8.
73. Rogers DF. Airway goblet cells: responsive and adaptable front-line defenders. Eur Respir J 1994; 7:1690-1706.
74. National Institutes of Health. Global Initiative for Asthma: Pocket Guide for Asthma Management and Prevention. Bethesda: National Institutes of Health, National Heart, Lung and Blood Institute, 2002, vol. Publication no. 02-3659.
75. Culpitt SV, Rogers DF. Evaluation of current pharmacotherapy of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2000; 1:1007-1020.
76. Barnes PJ, Ito K, Adcock IM. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 2004; 363:731-733.
77. Rogers DF. Mucoactive drugs for asthma and COPD: any place in therapy? Expert Opin Investig Drugs 2002; 11:15-35.
78. Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic broncho-pulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 2000; 22:209-221.
79. Stey C, Steurer J, Bachmann S, Medici TC, Tramer MR. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J 2000; 16:253-262.
80. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. Br Med J 2001; 322:1271-1274.
81. Grandjean EM, Berthet PH, Ruffmann R, Leuenberger P. Cost-effectiveness analysis of oral N-acetylcysteine as a preventive treatment in chronic bronchitis. Pharmacol Res 2000; 42:39-50.
82. Dekhuijzen PN. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J 2004; 23:629-636.
83. Moretti M, Bottrighi P, Dallari R, Da Porto R, Dolcetti A, Grandi P, Garuti G, Guffanti E, Roversi P, De Gugliemo M, Potena A. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study. Drugs Exp Clin Res 2004; 30:143-152.
84. MacNee W. Oxidative stress and lung inflammation in airways disease. Eur J Pharmacol 2001; 429:195-207.
85. Montuschi P, Kharitonov SA, Barnes PJ. Exhaled carbon monoxide and nitric oxide in COPD. Chest 2001; 120:496-501.
86. Wright DT, Fischer BM, Li C, Rochelle LG, Akley NJ, Adler KB. Oxidant stress stimulates mucin secretion and PLC in airway epithelium via a nitric oxide-dependent mechanism. Am J Physiol 1996; 271:L854-L861.
87. Burgel PR, Nadel JA. Roles of epidermal growth factor receptor activation in epithelial cell repair and mucin production in airway epithelium. Thorax 2004; 59:992-996.
88. Rhee CS, Majima Y, Arima S, Jung HW, Jinn TH, Min YG, Sakakura Y. Effects of clarithromycin on rheological properties of nasal mucus in patients with chronic sinusitis. Ann Otol Rhinol Laryngol 2000; 109:484-487.
89. Suez D, Szefler SJ. Excessive accumulation of mucus in children with asthma: a potential role for erythromycin? A case discussion. J Allergy Clin Immunol 1986; 77:330-334.
90. Marom ZM, Goswami SK. Respiratory mucus hypersecretion (bronchorrhea): a case discussion - possible mechanisms(s) and treatment. J Allergy Clin Immunol 1991; 87:1050-1055.
91. Shibuya Y, Wills PJ, Cole PJ. The effect of erythromycin on mucociliary transportability and rheology of cystic fibrosis and bronchiectasis sputum. Respiration 2001; 68:615-619.
92. Gorrini M, Lupi A, Viglio S, Pamparana F, Cetta G, Iadarola P, Powers JC, Luisetti M. Inhibition of human neutrophil elastase by erythromycin and flurythromycin, two macrolide antibiotics. Am J Respir Cell Mol Biol 2001; 25:492-499.
93. Shimizu T, Shimizu S, Hattori R, Gabazza EC, Majima Y. In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells. Am J Respir Crit Care Med 2003; 168:581-587.
94. Barnes PJ. Current and future therapies for airway mucus hypersecretion. Novartis Found Symp 2002; 248:237-249.
95. Donnelly LE, Rogers DF. Therapy for chronic obstructive pulmonary disease in the 21st century. Drugs 2003; 63:1973-1998.
96. Tesfaigzi Y, Fischer MJ, Daheshia M, Green FH, De Sanctis GT, Wilder JA. Bax is crucial for IFN-gamma-induced resolution of allergen-induced mucus cell metaplasia. J Immunol 2002; 169:5919-5925.
97. Herbst RS, Frankel SR. Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer. Clin Cancer Res 2004; 10:4245s-4248s.
98. Bonomi P. Clinical studies with non-iressa EGFR tyrosine kinase inhibitors. Lung Cancer 2003; 41(suppl 1):S43-S48.
99. Adler KB, Holden-Stauffer WJ, Repine JE. Oxygen metabolites stimulate release of high-molecular-weight glycoconjugates by cell and organ cultures of rodent respiratory epithelium via an arachidonic acid-dependent mechanism. J Clin Invest 1990; 85:75-85.
100. Rogers DF. Motor control of airway goblet cells and glands. Respir Physiol 2001; 125:129-144.
101. Rogers DF. Pharmacological regulation of the neuronal control of airway mucus secretion. Curr Opin Pharmacol 2002; 2:249-255.
102. Rogers DF. Tachykinin receptor antagonists for asthma and COPD. Expert Opin Ther Pat 2001; 11:1097-1121.
103. Caterina MJ, Julius D. The vanilloid receptor: a molecular gateway to the pain pathway. Annu Rev Neurosci 2001; 24:487-517.
104. Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 2001; 276:36059-36062.
105. Tesfaigzi Y, Kluger M, Kozak W. Clinical and cellular effects of cytochrome P-450 modulators. Respir Physiol 2001; 128:79-87.
106. Li Y, Martin LD, Spizz G, Adler KB. MARCKS protein is a key molecule regulating mucin secretion by human airway epithelial cells in vitro. J Biol Chem 2001; 276:40982-40990.
107. Singer M, Martin LD, Vargaftig BB, Park J, Gruber AD, Li Y, Adler KB. A MARCKS-related peptide blocks mucus hypersecretion in a mouse model of asthma. Nat Med 2004; 10:193-196.
108. Evans C, Kheradmand F, Corry D, Tuvim M, Densmore C, Waldrep C, Knight V, Dickey B. Gene therapy of mucus hypersecretion in experimental asthma. Chest 2002; 121:90S-91S.
109. O'Donnell RA, Richter A, Ward J, Angco G, Mehta A, Rousseau K, Swallow DM, Holgate ST, Djukanovic R, Davies DE, Wilson SJ. Expression of ErbB receptors and mucins in the airways of long term current smokers. Thorax 2004; 59:1032-1040.
110. Longphre M, Li D, Li J, Matovinovic E, Gallup M, Samet JM, Basbaum CB. Lung mucin production is stimulated by the air pollutant residual oil fly ash. Toxicol Appl Pharmacol 2000; 162:86-92.
111. Shim JJ, Dabbagh K, Takeyama K, Burgel PR, Dao-Pick TP, Ueki IF, Nadel JA. Suplatast tosilate inhibits goblet-cell metaplasia of airway epithelium in sensitized mice. J Allergy Clin Immunol 2000; 105:739-745.
112. Wang B, Lim DJ, Han J, Kim YS, Basbaum CB, Li JD. Novel cytoplasmic proteins of nontypeable Haemophilus influenzae up-regulate human MUC5AC mucin transcription via a positive p38 mitogen-activated protein kinase pathway and a negative phosphoinositide 3-kinase-Akt pathway. J Biol Chem 2002; 277:949-957.
113. Atherton HC, Jones G, Danahay H. IL-13-induced changes in the goblet cell density of human bronchial epithelial cell cultures: MAP kinase and phosphatidylinositol 3-kinase regulation. Am J Physiol, Lung Cell Mol Physiol 2003; 285:L730-L739.
114. Zhou Y, Shapiro M, Dong Q, Louahed J, Weiss C, Wan S, Chen Q, Dragwa C, Savio D, Huang M, Fuller C, Tomer Y, Nicolaides NC, McLane M, Levitt R. A calcium-activated chloride channel blocker inhibits goblet cell metaplasia and mucus overproduction. In: Mucus Hypersecretion in Respiratory Disease. Novartis Foundation Symposium. Chichester: Wiley, 2002; 248:150-165.
115. Nakanishi A, Morita S, Iwashita H, Sagiya Y, Ashida Y, Shirafuji H, Fujisawa Y, Nishimura O, Fujino M. Role of gob-5 in mucus overproduction and airway hyperresponsiveness in asthma. Proc Natl Acad Sci U S A 2001; 98:5175-5180.
116. Knight D. Talniflumate (Genaera). Curr Opin Investig Drugs 2004; 5:557-562.
117. Donnelly LE, Rogers DF. Antiproteases and retinoids for treatment of chronic obstructive pulmonary disease. Expert Opin Ther Pat 2003; 13:1345-1372.
118. Guzman K, Gray TE, Yoon JH, Nettesheim P. Quantitation of mucin RNA by PCR reveals induction of both MUC2 and MUC5AC mRNA levels by retinoids. Am J Physiol 1996; 271:L1023-L1028.
119. Yoon JH, Gray T, Guzman K, Koo JS, Nettesheim P. Regulation of the secretory phenotype of human airway epithelium by retinoic acid, triiodothyronine, and extracellular matrix. Am J Respir Cell Mol Biol 1997; 16:724-731.
120. Koo JS, Jetten AM, Belloni P, Yoon JH, Kim YD, Nettesheim P. Role of retinoid receptors in the regulation of mucin gene expression by retinoic acid in human tracheobronchial epithelial cells. Biochem J 1999; 338:351-357.
121. Apfel C, Bauer F, Crettaz M, Forni L, Kamber M, Kaufmann F, LeMotte P, Pirson W, Klaus M. A retinoic acid receptor alpha antagonist selectively counteracts retinoic acid effects. Proc Natl Acad Sci U S A 1992; 89:7129-7133.
122. Bhattacharyya SN, Manna B, Smiley R, Ashbaugh P, Coutinho R, Kaufman B. Smoke-induced inhalation injury: effects of retinoic acid and antisense oligodeoxynucleotide on stability and differentiated state of the mucociliary epithelium. Inflammation 1998; 22:203-214.
123. Tesfaigzi Y, Fischer MJ, Martin AJ, Seagrave J. Bcl-2 in LPS-and allergen-induced hyperplastic mucous cells in airway epithelia of Brown Norway rats. Am J Physiol, Lung Cell Mol Physiol 2000; 279:L1210-L1217.
124. Kellerman DJ. P2Y(2) receptor agonists: a new class of medication targeted at improved mucociliary clearance. Chest 2002; 121:2015-2055.
125. Roger P, Gascard JP, Bara J, de Montpreville VT, Yeadon M, Brink C. ATP induced MUC5AC release from human airways in vitro. Mediat Inflamm 2000; 9:277-284.
126. Jackson AD. Airway goblet-cell mucus secretion. Trends Pharmacol Sci 2001; 22:39-45.